



TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,
Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995

Date: 30-05-2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai — 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Submission of Audited Financial Results (Standalone & Consolidated) for the Quarter ended and Year End on 31ST March, 2026.

Please find the enclosed herewith Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended on **31ST March, 2026** along with Auditors Report thereon approved by the Board of Directors of the Company at its Meeting held on Saturday, May 30th, 2026 at Shop No 1 Building Name: Shivprasad Harihar Singh Compound, Block Sector: Jogeshwari East, Road: Caves Road. Pratap Nagar -Mumbai, Maharashtra, 400060 at 2:00 p.m., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

Dr. Ashish V. Rawandale
Managing Director
DIN: - 02005733





TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,
Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995

Date: 30.05.2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, in respect of Audit Report for the year ended March 31,2025.

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended vide SEBI Circular CIR/CFD/CMD/56/2016 dated May 27, 2016, we do hereby confirm that the Statutory Auditors of M/s Maheshwari and Co, Chartered Accountants, have issued an Audit Report with unmodified Opinion on Annual Audited (Standalone and Consolidated) Financial Results for the year ended on March 31, 2026.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

Dr. Ashish V. Rawandale
Managing Director
DIN: - 02005733



Independent Auditor's Report on Consolidated Annual Financial Results of Tejnakh Healthcare Limited for the year ended March 31, 2026 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**The Board of Directors of
Tejnakh Healthcare Limited**

Opinion

We have audited the accompanying statement of consolidated annual financial results of **Tejnakh Healthcare Limited** (hereinafter referred to as 'the Parent') and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), for the year ended March 31, 2026 (the 'Statement'), attached herewith, being submitted by the Group pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations).

In our opinion and to the best of our information and according to the explanations given to us, the Consolidated Financial Results for the year ended March 31, 2026:

- i. includes the financial results of the following entities:
 - Tejvedaant Healthcare Private Limited - Subsidiary
- ii. Are presented financial result in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Group for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph of *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Statement

This Statement has been prepared on the basis of the consolidated annual financial statements and has been approved by the Parent's Board of Directors. The Parent's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Office: 1302, Solaris One, Vijay Nagar, Opp. Teli Gali, Andheri (East), 400069

Head office: 10-11, Third Floor, Esplanade Building, 3 A K Naik Marg (Bestian Road), Near New Empire Cinema, Fort, CST, Mumbai 400 001

Tel.: (+91) 89764 36515, E-mail: vkasawa@maheshwariandco.in, Website: www.maheshwariandco.in



In preparing the Statement, the respective Board of Directors included in the group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and joint ventures to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

The Statement includes the results for the three months ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date consolidated figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For Maheshwari and Company

Chartered Accountant

Firm's Registration No.: 105834W



CA Vikas Asawa

Partner

Membership No.: 172133

UDIN: 26172133UXBTJZ4798



Place: Mumbai

Date: May 30, 2026



TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,
Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN : L85100MH2008PLC179034)
Statement of Consolidated Financial Results for quarter & year ended March 31, 2026
All amounts are in Indian Rupees lakhs

Particulars	Quarter ended			Year ended	
	Mar-26 (Refer Note 4)	Dec-25 Unaudited	Mar-25 (Refer Note 4)	Mar-26 Audited	Mar-25 Audited
REVENUE					
Revenue from operations (net)	255.29	261.62	321.48	1,078.69	1,289.71
Other income	13.63	7.02	7.21	39.30	40.43
Total Income	268.92	268.64	328.69	1,117.99	1,330.14
EXPENSES					
Cost of Materials Consumed	4.35	0.04	0.09	4.79	0.23
Purchases of stock-in-trade	24.03	25.07	29.27	102.16	124.58
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(6.33)	(0.31)	9.34	(5.17)	3.86
Employee benefits expense	31.06	33.41	39.07	139.28	152.63
Finance costs	(2.93)	3.89	1.00	9.56	37.62
Depreciation and amortization expense	35.91	36.39	17.45	142.81	90.99
Other expenses	130.90	134.49	172.99	559.94	601.09
Total Expenses	216.99	232.99	269.20	953.37	1,011.00
Profit/(Loss) before Exceptional Items & Tax	51.93	35.65	59.48	164.62	319.14
Exceptional Items					
Profit/(Loss) Before Tax	51.93	35.65	59.48	164.62	319.14
Tax expense:					
Current tax	22.03	5.09	21.10	43.19	85.10
Deferred tax	(4.96)	1.74	(3.95)	3.32	10.99
Profit/(Loss) for the period/year	34.86	28.82	42.33	118.11	223.05
Items not be reclassified to profit or loss :					
Remeasurement of defined employee benefit plans	(0.64)	0.63	2.53	1.26	2.53
Income tax credit(expense) relating to above items	0.23	(0.31)	(2.98)	(0.25)	(0.64)
Other Comprehensive Income/(Loss) for the year, net of tax	(0.41)	0.32	(0.45)	1.01	1.89
TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	34.45	29.14	41.88	119.12	224.94
Profit/(Loss) for the year attributable to:					
Equity holders of the parent	36.10	30.48	50.83	122.82	232.78
Non-controlling Interests	(1.23)	(1.63)	(8.50)	(4.71)	(9.73)
Other Comprehensive Income/(Loss) for the year attributable to:					
Equity holders of the parent	(0.26)	0.25	0.06	0.94	1.67
Non-controlling Interests	(0.15)	0.07	(0.51)	0.07	0.22
Total Comprehensive Income/(Loss) for the year attributable to:					
Equity holders of the parent	35.84	29.60	50.89	123.76	234.45
Non-controlling Interests	(1.38)	(0.46)	(9.01)	(4.64)	(9.51)
Paid Up Equity Share Capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the previous year				1,699.16	1,575.40
Earnings per share (EPS)					
Basic and Diluted Earing Per Share	0.17	0.14	0.21	0.61	1.15
		Not Annualized		Yearly	

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,
Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995

Kanwar





TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,
Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN:L85100MH2008PLC179034)
Consolidated Balance Sheet as at March 31, 2026
All amounts are in Indian Rupees lakhs

Particulars	As at March 31, 2026	As at March 31, 2025
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	1,829.30	1,904.53
Goodwill	168.70	210.88
Other Intangible Assets	0.95	0.99
Intangible Assets Under Development	169.25	133.25
Right-of-use assets	24.27	-
Financial Assets		
Investments	0.01	0.01
Other Financial Assets	222.93	184.95
Other Non-Current Assets	0.86	17.62
Income Tax Assets (Net)	58.27	4.00
Total Non-Current Assets	2,474.54	2,456.23
Current assets		
Inventories	83.17	79.00
Financial Assets		
Trade Receivables	217.53	184.90
Cash and Cash Equivalents	195.00	175.56
Bank Balances Other than above	7.74	3.58
Other Financial Assets	6.60	7.10
Other Current Assets	20.44	124.54
Total Current Assets	530.48	574.68
TOTAL ASSETS	3,005.02	3,030.91
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	1,015.68	1,015.68
Other Equity	1,699.16	1,575.40
Equity attributable to Owners of the Company	2,714.84	2,591.08
Non Controlling Interest	49.44	54.08
Total Equity	2,764.28	2,645.16
Liabilities		
Non Current Liabilities		
Financial Liabilities		
Borrowings	-	63.20
Lease	13.66	-
Other financial liabilities	0.07	44.75
Non Current Provision	14.20	17.69
Deferred Tax liabilities (Net)	146.40	142.83
Other Non Current Liabilities	3.63	8.64
Total Non Current Liabilities	177.96	277.11
Current Liabilities		
Financial Liabilities		
Borrowings	-	42.07
Lease Liabilities	10.96	-
Trade Payables	-	-
Total Outstanding dues of Micro and Small Enterprises	0.53	0.32
Total Outstanding dues of Creditors other than Micro and Small Enterprises	23.44	29.53
Other financial liabilities	12.97	19.01
Other Current Liabilities	9.09	10.28
Current Provision	5.79	7.43
Total Current Liabilities	62.78	108.64
TOTAL LIABILITIES	3,005.02	3,030.91

Sawant





TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com

Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED

CIN:L85100MH2008PLC179034

Consolidated Statement of Cash Flows for the year ended March 31, 2026

All amounts are in Indian Rupees lakhs

Particulars	For year ended March 31,2026	For year ended March 31,2025
CASH FLOWS FROM OPERATING ACTIVITIES:		
Profit before tax	164.62	319.14
Adjustments for:		
Depreciation and amortisation expense	142.81	90.99
Finance costs	9.56	37.62
Interest income (classified under investing activities)	(12.90)	(14.39)
Bad debts	7.51	1.78
Rental income (classified under investing activities)	(13.23)	-
(Gain) / Loss on sale of property, plant & equipment & Investment property	1.08	-
Provision for Gratuity	(3.87)	5.24
Change in operating assets and liabilities:		
(Increase)/Decrease in trade receivables	(40.14)	(134.34)
(Increase)/Decrease in inventories	(4.17)	1.90
Increase/(Decrease) in other financial assets	(40.29)	(127.86)
(Increase) /Decrease in Other assets	107.24	(100.27)
(Increase)/Decrease in trade payables	(5.88)	7.74
Increase/(Decrease) in Other financial liabilities	(50.72)	4.90
Increase/(Decrease) in other liabilities	(6.20)	(7.11)
Cash generated from operations	255.42	85.34
Less: Income taxes (paid)/refund	(83.84)	(47.01)
Net cash flows generated/(used) from operating activities (A)	171.58	38.33
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for property, plant and equipment and intangibles	(51.48)	(24.79)
Proceeds from sale of property, plant and equipment	2.25	-
Proceeds from deletion of intangible	-	139.12
Intangible asset under development	-	(26.00)
Movement in other bank balance	(4.16)	249.36
Interest received	12.90	14.39
Dividend received	(1.08)	-
Rental income	13.23	-
Net cash flows generated/(used) in investing activities (B)	(28.34)	352.08
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayment of current borrowings	(42.07)	(347.74)
Repayment of non current borrowings	(63.20)	-
Principal element of lease payment	(8.97)	(1.56)
Interest paid	(9.56)	(37.62)
Net cash flows generated/(used) in financing activities (C)	(123.80)	(386.92)
Net increase (decrease) in cash and cash equivalents (A+B+C)	19.44	3.49
Cash and Cash Equivalents at the beginning of the financial year	175.56	172.07
Cash and Cash Equivalents at end of the year	195.00	175.56
Reconciliation of cash and cash equivalents as per the cash flow statement:		
Cash and cash equivalents as per above comprise of the following:		
Balances with bank in current accounts	124.41	61.63
Cash on hand	70.59	113.93
Balances per statement of cash flows	195.00	175.56

Somavak





TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com

Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Notes to the Consolidated Financial Results for the year ended March 31, 2026

1. The above Consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 30, 2026.
2. The above consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. The accompanying consolidated financial results include the financial results of the subsidiary company, Tejvedaant Healthcare Private Limited.
4. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
5. The Company's business activity primarily falls within a single reportable business segment namely "Medical and Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".
6. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the 'New Labour Codes'). These codes have been made effective from November 21, 2025.

The Group has remeasured the gratuity liability as at December 31, 2025 and March 31, 2026 in accordance with the provisions of the New Labour Codes. Based on such remeasurement, there was a reversal of gratuity liability, which has been recognized as Other Income in the current reporting period. Further, no material additional liability in respect of compensated absences and provident fund has arisen pursuant to the aforesaid codes. The Government is in the process of notifying the relevant rules under the New Labour Codes, and the consequential impact, if any, will be evaluated and accounted for in accordance with the applicable accounting standards in the period in which such rules are notified.
7. Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, wherever applicable, which are not material.

For and behalf of Board of Directors of
Tejnaksh Healthcare Limited

Dr. A. V. Rawandale
Managing Director
DIN: 02005733



Date: May 30, 2026
Place: Mumbai

Independent Auditor's Report on Standalone Annual Financial Results of Tejnakhsh Healthcare Limited for the year ended March 31, 2026 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**The Board of Directors of
Tejnakhsh Healthcare Limited**

Opinion

We have audited the accompanying statement of standalone annual financial results ("the statement") of **Tejnakhsh Healthcare Limited** ("hereinafter referred to as 'the Company') for the year ended March 31, 2026, attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations).

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:


- i. Are presented financial result in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph of *Auditor's Responsibilities for the Audit of the Statement* section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management and Those Charged with Governance for the Statement

This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.



Office: 1302, Solaris One, Vijay Nagar, Opp. Teli Gali, Andheri (East), 400069

Head office: 10-11, Third Floor, Esplanade Building, 3 A K Naik Marg (Bestian Road), Near New Empire Cinema, Fort, Mumbai 400 001

Tel.: (+91) 89764 36515, **E-mail:** vkasawa@maheshwariandco.in, **Website:** www.maheshwariandco.in

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The Statement includes the results for the three months ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For Maheshwari and Company

Chartered Accountant

Firm's Registration No.: 105834W

**CA Vikas Asawa**

Partner

Membership No.: 172133

UDIN: 26172133HUUCNJ2453**Place:** Mumbai**Date:** May 30, 2026



TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,
Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN: L85100MH2008PLC179034)
Standalone Statement of Profit & Loss
All amounts are in Indian Rupees lakhs

Particulars	Quarter Ended			Year Ended	
	Mar-26 (Refer Note 3)	Dec-25 Unaudited	Mar-25 (Refer Note 3)	Mar-26 Audited	Mar-25 Audited
REVENUE					
Revenue from operations (net)	177.05	169.08	240.43	717.72	879.31
Other income	14.79	5.98	6.23	37.42	35.73
Total Income	191.84	175.05	246.66	755.14	915.04
EXPENSES					
Cost of Materials Consumed	4.35	0.04	0.09	4.79	0.23
Purchases of stock-in-trade	11.94	9.33	13.88	43.69	57.18
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(11.79)	11.68	6.82	(3.07)	7.51
Employee benefits expense	15.45	17.98	21.67	77.69	76.91
Finance costs	0.68	3.89	4.02	13.17	37.60
Depreciation and amortization expense	33.08	32.51	15.01	131.32	78.84
Other expenses	76.58	70.02	81.59	308.99	290.38
Total Expenses	130.29	145.44	143.08	576.58	548.65
Profit before Exceptional Items & Tax	61.55	29.61	103.58	178.56	366.39
Exceptional Items	-	-	-	-	-
Profit/(Loss) Before Tax	61.55	29.61	103.58	178.56	366.39
Tax expense:					
Current tax	22.03	5.09	21.13	43.19	83.34
Deferred tax	(10.89)	1.74	7.09	(2.61)	20.90
Profit/(Loss) for the period/year	50.41	22.78	75.35	137.98	262.15
Other Comprehensive Income/(Loss)					
Items not be reclassified to profit or loss :					
Remeasurement of defined employee benefit plans	(0.05)	0.35	(0.49)	0.98	1.37
Income tax effect on above	0.01	(0.09)	0.13	(0.25)	(0.34)
Total Other Comprehensive income for the year, net of tax	(0.04)	0.26	(0.36)	0.73	1.03
Total Comprehensive Income (Net of Tax) for the Period/Year	50.37	23.04	74.99	138.71	263.18
Paid Up Equity Share Capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the period	-	-	-	1,663.87	1,525.16
Earnings per share (EPS)					
Basic and Diluted Earing Per Share	0.39	0.11	0.37	0.68	1.29
	Not Annualized	Not Annualized	Not Annualized		





TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,

Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN: L85100MH2008PLC179034)
Standalone Balance Sheet As At March 31, 2026
All amounts are in Indian Rupees lakhs

Particulars	As at March 31, 2026	As at March 31, 2025
ASSETS		
Non-current assets		
Property, plant and equipment	1,738.14	1,802.00
Goodwill	168.70	210.88
Other intangible assets	0.95	0.99
Intangible assets under development	169.25	133.25
ROU assets	24.27	-
Financial assets		
- Investment	106.01	106.01
- Other financial assets	226.54	143.57
Income tax assets (net)	43.04	4.32
Other non current assets	0.74	4.00
Total non-current assets	2,477.64	2,405.02
Current assets		
Inventories	39.02	36.95
Financial assets		
- Trade receivables	201.73	175.27
- Cash and cash equivalents	178.55	160.88
- Other bank balances	7.74	3.58
- Other financial assets	3.53	4.03
Other current assets	13.47	114.67
Total current assets	444.04	495.38
Total assets	2,921.68	2,900.40
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,015.68	1,015.68
Other equity	1,663.87	1,525.16
Total equity	2,679.55	2,540.84
Liabilities		
Non-current liabilities		
Financial liabilities		
- Borrowings	-	63.20
- Lease Liability	13.66	-
- Other Financial Liability	30.07	44.75
Provisions	8.78	11.35
Deferred Tax liabilities (Net)	146.40	148.76
Other non current liabilities	3.63	8.64
Total non-current liabilities	202.54	276.70
Current liabilities		
Financial liabilities		
- Borrowings	-	42.07
- Lease liability	10.96	-
- Trade payables	-	-
Total outstanding dues of micro and small enterprises ; and	-	0.06
Total outstanding dues of creditors other than micro enterprises and small enterprises	11.07	15.38
Other Financial Liabilities	5.03	6.21
Other current liabilities	7.87	13.04
Provisions	4.66	6.10
Total current liabilities	39.59	82.86
Total liabilities	242.13	359.56
Total equity and liabilities	2,921.68	2,900.40


Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,

Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995





TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East,
Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN: L85100MH2008PLC179034)
Standalone Cash Flow Statement
All amounts are in Indian Rupees lakhs

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Cash flow from/(used in) operating activities		
Profit/(loss) before tax	178.56	366.39
Adjustment for:		
Depreciation and amortisation expense	131.32	78.84
Interest Income	(12.18)	(13.42)
Finance costs	13.17	37.60
Employee Benefit expense (Gratuity)	(3.04)	3.17
Operating cash flows before working capital changes	307.83	472.58
Changes in working capital		
Adjustments for (increase) / decrease in operating assets:		
Trade receivables	(26.46)	(130.07)
Inventories	(2.07)	7.51
Other Financial assets	(92.23)	(112.91)
Other assets	104.46	(94.42)
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	(4.37)	1.73
Other Financial Liabilities	(15.85)	(46.09)
Other liabilities	(10.18)	(4.43)
Cash generated from / (used in) operations	261.13	93.90
Income taxes (paid)/refund (net)	(81.91)	(49.75)
Net Cash from / (used in) operating activities	(A) 179.22	44.15
Cash flow from investing activities		
Purchase of property, plant and equipment (including capital work-in-progress, intangibles assets and RoU)	(51.36)	(44.19)
Proceeds from sale of property, plant and equipment (including capital work-in-progress and intangibles)	2.25	139.12
Movement in other bank balance	(4.16)	249.36
Interest received	12.18	13.42
Net Cash from / (used in) investing activities	(B) (41.09)	357.71
Cash flow from financing activities		
Principal element of lease payment	(8.97)	(0.76)
Repayment of long-term borrowings	(105.27)	(347.74)
Interest paid	(6.22)	(33.67)
Cash generated from / (used in) financing activities	(C) (120.46)	(382.17)
Net increase/(decrease) in cash and cash equivalents	17.67	19.69
Cash and cash equivalent at beginning of the year	160.88	141.19
Cash and cash equivalent at end of the year	178.55	160.88
Reconciliation of cash and cash equivalents as per the cash flow statement:		
Cash and cash equivalents as per above comprise of the following:		
Balance with banks in current accounts	109.49	48.49
Cash on hand	69.06	112.39
Balances per statement of cash flows	178.55	160.88

Lawanda
Tejnaksh Healthcare Limited
MUMBAI



TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060

Head Office : Institute of Urology Sakri Raod, Dhule - 424001

CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com

Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Notes to the Standalone Financial Results for the year ended March 31, 2026

1. The above standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 30, 2026.
2. The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
4. The Company's business activity primarily falls within a single reportable business segment namely " Medical and Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108-"Segment Reporting".
5. The Government of India has Consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the 'New Labour Codes'). These codes have been made effective from November 21, 2025.
The company has remeasured the gratuity liability as at December 31, 2025 and March 31, 2026 in accordance with the provisions of the New Labour Codes. Based on such remeasurement, there was a reversal of gratuity liability, which has been recognized as Other Income in the current reporting period. Further, no material additional liability in respect of compensated absences and provident fund has arisen pursuant to the aforesaid codes. The Government is in the process of notifying the relevant rules under the New Labour Codes, and the consequential impact, if any, will be evaluated and accounted for in accordance with the applicable accounting standards in the period in which such rules are notified.
6. Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, wherever applicable, which are not material.

For and behalf of Board of Directors of

Tejnaksh Healthcare Limited

Dr. A. V. Rawandale
Managing Director
DIN: 02005733



Date: May 30, 2026
Place: Mumbai